Investor Presentation Q1 2018

Novo Nordisk at a glance Investor Presentation First three months of 2018 Slide 21 Global leader in diabetes care • A focused pharmaceutical company with leading positions in diabetes, haemophilia and growth hormone • Significant growth opportunities driven by the diabetes pandemic, fuelled by global presence and strong research • and development pipeline High barriers to entry in biologics • Operating profit growth targeting 5% yearly on average (measured in local currencies) Earnings conversion to cash targeting 90% • Cash generated returned to shareholders Global insulin market leadership Global insulin market share: 46% Region Europe: Market share 44% North America Operations: Region China: Market share 52% Region Japan & Korea: Market share 50% Market share 39% Region AAMEO: Market share 56% Region Latin America: Market share 43% Global/regional headquarter Source: IQVIA MAT Feb 2018 volume figures AAMEO: Africa, Asia, Middle East & Oceania Manufacturing R&D facility changing diabetes novo nordisk

View entire presentation